{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:22:43Z","timestamp":1790997763231,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,8]]},"DOI":"10.4269\/ajtmh.19-0931","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T03:01:03Z","timestamp":1589252463000},"page":"308-314","source":"Crossref","is-referenced-by-count":31,"title":["Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (FungisomeTM) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy"],"prefix":"10.4269","volume":"103","author":[{"given":"Rama Prosad","family":"Goswami","sequence":"first","affiliation":[{"name":"Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehebubar","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhen","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu Kumar","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Prosad","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"b2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"b3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin Infect Dis"},{"key":"b4","doi-asserted-by":"crossref","first-page":"e1657","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"b5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"b6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0035-9203(99)90036-6","article-title":"Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis","volume":"93","author":"Bodhe","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"b7","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1371\/journal.pntd.0000764","article-title":"A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a shortcourse liposomal amphotericin B therapy","volume":"27","author":"Mondal","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"b8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4269\/ajtmh.14-0657","article-title":"Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome\u2122)","volume":"94","author":"Goswami","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"b9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4269\/ajtmh.14-0259","article-title":"Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study","volume":"92","author":"Sundar","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"b10","volume-title":"Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS","year":"2006"},{"key":"b11","first-page":"1","volume-title":"Control of the Leishmaniases. Report of a WHO Expert Committee. World Health Organization Technical Report Series 949","year":"2010"},{"key":"b12","doi-asserted-by":"crossref","first-page":"e0005635","DOI":"10.1371\/journal.pntd.0005635","article-title":"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"30","author":"Rahman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"b13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4269\/ajtmh.16-0432","article-title":"Protective efficacy of secondary prophylaxis against visceral leishmaniasis in human immunodeficiency virus coinfected patients over the past 10 years in eastern India","volume":"96","author":"Goswami","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"b14","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.4049\/jimmunol.179.8.5592","article-title":"IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of leishmania donovani infection in India","volume":"179","author":"Saha","year":"2007","journal-title":"J Immunol"},{"key":"b15","first-page":"38","article-title":"Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India","volume":"128","author":"Thakur","year":"2008","journal-title":"Indian J Med Res"},{"key":"b16","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/JCM.05966-11","article-title":"Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India","volume":"50","author":"Pandey","year":"2012","journal-title":"J Clin Microbiol"},{"key":"b17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/0019-5154.110848","article-title":"Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis","volume":"58","author":"Koley","year":"2013","journal-title":"Indian J Dermatol"},{"key":"b18","doi-asserted-by":"crossref","first-page":"e2611","DOI":"10.1371\/journal.pntd.0002611","article-title":"Post kala-azar dermal leishmaniasis following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"b19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/0022-3859.118046","article-title":"Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India","volume":"59","author":"Das","year":"2016","journal-title":"J Postgrad Med"},{"key":"b20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s13071-016-1721-0","article-title":"The immunology of post-kala-azar dermal leishmaniasis (PKDL)","volume":"9","author":"Zijlstra","year":"2016","journal-title":"Parasit Vectors"},{"key":"b21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.pt.2019.06.007","article-title":"Post-kala-azar dermal leishmaniasis as a reservoir for visceral leishmaniasis transmission","volume":"35","author":"Le Rutte","year":"2019","journal-title":"Trends Parasitol"},{"key":"b22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:24:30Z","timestamp":1722867870000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajtmh.org\/doi\/10.4269\/ajtmh.19-0931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,8]]}},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0931","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]}}}